Physician profile
Kacey Sullivan
NPI 1639659733
$2,423.68
in general payments reported to CMS, 2019-2025
9 companies · $17.97 in 2025
The $17.97 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.22 · 2022: $311 · 2023: $1,728 · 2024: $342 · 2025: $17.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,488 · Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,488.10 |
| Food and Beverage | $599.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,652.73 | 2023 | Stratafix |
| Janssen Pharmaceuticals, INC | $327.40 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $306.28 | 2022-2024 | |
| Amgen INC. | $35.70 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $27.10 | 2022 | |
| Cordis US Corp. | $22.77 | 2024 | Infiniti |
| Solventum Corporation | $18.42 | 2024 | Activ.A.C., V.A.C.Ulta, V.A.C. Veraflo |
| Kiniksa Pharmaceuticals International, Plc | $17.08 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $16.20 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.